Undisclosed TARP peptide vaccine / National Cancer Institute, PDS Biotech - LARVOL DELTA

PDS Biotechnology Licenses Protein for the Treatment of Acute Myeloid Leukemia, Prostate and Breast Cancers from National Cancer Institute (GlobeNewswire) - "PDS Biotechnology Corporation...announced a licensing agreement with the National Cancer Institute (NCI) for intellectual property related to the NCI’s proprietary tumor-associated and immunologically active T-cell receptor gamma alternate reading frame protein (TARP)....The worldwide, non-exclusive license secures rights for the proprietary TARP antigen from the NCI with patent protection through 2034."

Licensing / partnership • Patent • Oncology